Scientists have used molecular simulations to understand resistance to osimertinib — an anticancer drug used to treat types of lung cancer.
Scientists from the Universities of Bristol and Parma, Italy, have used molecular simulations to understand resistance to osimertinib — an anticancer drug used to treat types of lung cancer.
Osimertinib binds tightly to a protein, epidermal growth factor receptor (EGFR), which is overexpressed in many tumours.
EGFR is involved in a pathway that signals for cell proliferation, and so is a target for drugs. Blocking the action of EGFR (inhibiting it) can switch it off, and so is a good way to treat the disease.
